This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bourhis, J. Articles by Bénard, J. Search for Related Content PubMed PubMed Citation Articles by Bourhis, J. Articles by Bénard, J.

Expression of a Human Multidrug Resistance Gene in Ovarian Carcinomas¹

Laboratoire de Pharmacologie Clinique et Moléculaire, Institut Gustave Roussy, 94805 Villejuif Cedex, France [J. B., G. R., J. Bé.], and Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [L. J. G., I. P., M. M. G.]

Expression of the human MDR1 gene has been shown to confer the multidrug resistance (MDR) phenotype to sensitive cells. To investigate the possible contribution of the MDR phenotype to chemoresistance in ovarian carcinoma, we have analyzed MDR1 gene expression in fresh carcinoma specimens from 50 patients. Fifteen received chemotherapy before surgery and were judged as poor responders. Thirty-five patients did not receive any drug before surgery. Control tissues were lymphocytes from 7 patients. Total RNAs were analyzed by Northern and slot blot hybridization techniques using human MDR1 complementary DNA and human -actin complementary DNA probes sequentially as qualitative and quantitative controls. MDR1 transcripts (4.5 kilobases) were observed in the RNA preparations obtained from 3 of 10 patients who were treated with doxorubicin or vincristine, 2 drugs known to select the MDR phenotype in vitro. In 40 other RNA preparations obtained from 35 untreated patients and 5 patients treated exclusively with cyclophosphamide and cis-platinum, no transcript could be detected. Using the exact Fisher test, the difference between the 2 groups was found to be significant (P < 0.01). The three tumors with elevated MDR1 expression did not show MDR1 DNA amplification. Our study suggests that, in spite of the weak occurrence of the MDR process in patients with ovarian cancers, MDR1 expression can be related to previous treatment with doxorubicin or vincristine. These results favor the expression of the MDR1 gene as one of the determinants involved in the acquired chemoresistance of ovarian cancers.

¹ This work was supported by Association pour la Recherche sur le Cancer (Villejuif, France) and Institut Gustave Roussy (Contrat de Recherche Clinique N. 88 D20).

² To whom requests for reprints should be addressed.

Received 1/18/89. Revised 6/ 7/89. Accepted 6/16/89.

This article has been cited by other articles:

				H. Tsuda, Y. M. Ito, Y. Ohashi, K.-K. Wong, Y. Hashiguchi, W. R. Welch, R. S. Berkowitz, M. J. Birrer, and S. C. Mok Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses Clin. Cancer Res., October 1, 2005; 11(19): 6880 - 6888. [Abstract] [Full Text] [PDF]

				H. Tanaka, N. Ohshima, M. Ikenoya, K. Komori, F. Katoh, and H. Hidaka HMN-176, an Active Metabolite of the Synthetic Antitumor Agent HMN-214, Restores Chemosensitivity to Multidrug-Resistant Cells by Targeting the Transcription Factor NF-Y Cancer Res., October 15, 2003; 63(20): 6942 - 6947. [Abstract] [Full Text] [PDF]

				Y. Ohishi, Y. Oda, T. Uchiumi, H. Kobayashi, T. Hirakawa, S. Miyamoto, N. Kinukawa, H. Nakano, M. Kuwano, and M. Tsuneyoshi ATP-binding Cassette Superfamily Transporter Gene Expression in Human Primary Ovarian Carcinoma Clin. Cancer Res., December 1, 2002; 8(12): 3767 - 3775. [Abstract] [Full Text] [PDF]

				M. Mubashar, K. J. Harrington, K. S. Chaudhary, E.-N. Lalani, G. W. Stamp, D. Sinnett, D. M. Glass, and A. M. Peters 99mTc-Sestamibi Imaging in the Assessment of Toremifene as a Modulator of Multidrug Resistance in Patients with Breast Cancer J. Nucl. Med., April 1, 2002; 43(4): 519 - 525. [Abstract] [Full Text] [PDF]

				J. Albertus and R. Laine Enhanced xenobiotic transporter expression in normal teleost hepatocytes: response to environmental and chemotherapeutic toxins J. Exp. Biol., January 1, 2001; 204(2): 217 - 227. [Abstract] [PDF]

				A. Lau, S. Nightingale, G. P. Taylor, T. W. Gant, and A. J. Cann Enhanced MDR1 Gene Expression in Human T-Cell Leukemia Virus-I-Infected Patients Offers New Prospects for Therapy Blood, April 1, 1998; 91(7): 2467 - 2474. [Abstract] [Full Text] [PDF]